Published: Thu, January 18, 2018
Industry | By Terrell Bush

Vertex Pharmaceuticals (VRTX) Rating Increased to Strong-Buy at Zacks Investment Research


Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company's stock valued at $2,188,196,000 after purchasing an additional 504,982 shares during the period.

The stock increased 0.82% or $1.28 during the last trading session, reaching $156.99. The average 1-year price target for (MNST) reveals an average price target of $68 per share. H.C. Wainwright downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, October 24 to "Neutral" rating. It has outperformed by 28.99% the S&P500.

Liberum Capital have a GBX 300.00 price target on the stock. The stock volatility for the week was 1.99% while for the month was 2.27%.

Since July 31, 2017, it had 0 insider buys, and 24 insider sales for $65.06 million activity. $324,976 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Parini Michael.

In other Vertex Pharmaceuticals news, CFO Thomas Graney sold 777 shares of the firm's stock in a transaction on Tuesday, January 2nd. Institutional investors and hedge funds own 95.29% of the company's stock.

Vertex Pharmaceuticals Inc Ma CEO & President Jeffrey Leiden on the January 17, 2018 unloaded a total of 99,563 shares of the Massachusetts-based Vertex Pharmaceuticals Inc Ma worth about $15,630,614 U.S. Dollars. $1.68 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Bhatia Sangeeta N. Sachdev Amit sold 40,000 shares worth $5.80 million.

Will International Business Machines Corp (NYSE:IBM) End Its Losing Streak?
CIBC Asset Management Inc's holdings in International Business Machines were worth $12,285,000 as of its most recent SEC filing. The technology company reported $3.30 EPS for the quarter, topping the consensus estimate of $3.28 by $0.02. (NASDAQ:BIIB).

Investors sentiment increased to 1.62 in Q3 2017.

The stock increased 1.09% or $0.11 during the last trading session, reaching $10.2.

Vertex Pharmaceuticals (NASDAQ:VRTX)'s stock had its "buy" rating reiterated by stock analysts at JPMorgan Chase & Co.in a research report issued to clients and investors on Tuesday, January 9th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.49. Shine Invest Advisory Incorporated reported 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ww Asset Mngmt Incorporated owns 24,087 shares or 0.12% of their United States portfolio. Commonwealth Of Pennsylvania School Empls Retrmt has 0.05% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 20,504 shares. Analysts expect that Vertex Pharmaceuticals Incorporated will post $0.83 EPS for the current year. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an "outperform" rating in a research note on Wednesday, October 18th. Eii Management holds 120,000 shares. Moreover, Old Mutual Global Invsts (Uk) Ltd has 1.91% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1.20 million shares.

Investors may also want to take a longer-term look at company shares. Manning & Napier Advisors Ltd Com has invested 1.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hong Kong-based Parametrica Mgmt has invested 0.13% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 17, 2017 and is uptrending. The target implies a -13.23% decrease from where the shares are now trading. It also reduced its holding in Pacific Ethanol Inc (NASDAQ:PEIX) by 67,299 shares in the quarter, leaving it with 18,526 shares, and cut its stake in Korn Ferry Intl (NYSE:KFY). Bank Of America Corp (NYSE:BAC) was reduced too.

Analysts have given a mean recommendation of 1.90 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Therefore 86% are positive. During the last 52 weeks, the (NASDAQ:VRTX) price has been as high as $167.85 and as low as $79.78. The firm has "Buy" rating given on Wednesday, September 6 by Robert W. Baird. On Friday, June 2 the stock rating was upgraded by Oppenheimer to "Outperform". Jefferies maintained the stock with "Buy" rating in Thursday, October 26 report. On Wednesday, July 19 the stock rating was upgraded by Barclays Capital to "Overweight". The rating was upgraded by Wells Fargo on Friday, February 17 to "Outperform". The stock has "Buy" rating by Cantor Fitzgerald on Thursday, October 19. (NYSE:BGS) rating on Tuesday, August 8. The company was maintained on Monday, June 12 by Canaccord Genuity. The market capitalization of the company is $43.93 Billion. The stock has been active on the tape, now trading at $157.93, down from yesterday's close by -0.30%. Prelude Capital Ltd holds 19,755 shares or 0.27% of its portfolio. It has underperformed by 81.28% the S&P500. Schaper Benz & Wise Investment Counsel Inc who had been investing in B&G Foods for a number of months, seems to be bullish on the $2.22 billion market cap company. The firm designs, sources, markets, and sells clothing, shoes, accessories, and beauty products through the Websites to a market of 16 to 30 year old consumers. It has a 18.42 P/E ratio. It offers its products for men, women, and children. Therefore 50% are positive. DA Davidson started coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. The rating was initiated by Stifel Nicolaus with "Buy" on Tuesday, December 1. The stock has "Buy" rating by Maxim Group on Thursday, July 27. As per Thursday, October 26, the company rating was maintained by Jefferies. The rating was initiated by Oppenheimer on Thursday, October 12 with "Buy".

Like this: